Meeting
2020 Genitourinary Cancers Symposium
A randomized, double-blinded clinical trial of royal jelly intake for anticancer effects and suppressing adverse events in renal cell carcinoma patients treated with tyrosine kinase inhibitors.
Authors
Yasuyoshi Miyata
Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Yasuyoshi Miyata , Kojiro Ohba , Tomohiro Matsuo , Kensuke Mitsunari , Hideki Sakai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 697)
Abstract #
697
Poster Bd #
G17
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Adjuvant therapy in high-risk renal cell cancer: A systematic review and cumulative meta-analysis.
First Author: Rabbia Siddiqi
Poster
2019 ASCO Annual Meeting
Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).
First Author: Daniel Vargas Almeida
Poster
2016 Genitourinary Cancers Symposium
Real world chart review of adverse event management in patients taking tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC) by line of therapy (LoT).
First Author: Sandhya Srinivas
Poster
2023 ASCO Genitourinary Cancers Symposium
Estimated cost of adverse event (AE) management for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with a VEGFR TKI.
First Author: Jeffrey Thomas Yorio